These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35078686)

  • 1. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma.
    Wang SY; Su TH; Chen BB; Liu CJ; Liu CH; Yang HC; Tseng TC; Chen PJ; Kao JH
    J Formos Med Assoc; 2022 Aug; 121(8):1579-1587. PubMed ID: 35078686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis.
    Su TH; Peng CY; Chang SH; Tseng TC; Liu CJ; Chen CL; Liu CH; Yang HC; Chen PJ; Kao JH
    J Formos Med Assoc; 2022 Mar; 121(3):703-711. PubMed ID: 34452785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
    Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L
    Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
    Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
    Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of PIVKA-II and AFP for the non-objective response of HBV-associated hepatocellular carcinoma after transarterial chemoembolization: a prospective study.
    Wang L; Yang X; Wang J; Yu G
    Eur J Gastroenterol Hepatol; 2023 Dec; 35(12):1410-1415. PubMed ID: 37942758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
    Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
    Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological response under treatment and prognostic value of protein induced by vitamin K absence or antagonist-II in a French cohort of patients with hepatocellular carcinoma.
    Payancé A; Dioguardi Burgio M; Peoc'h K; Achahboun M; Albuquerque M; Devictor J; Chor H; Manceau H; Soubrane O; Durand F; Castera L; Bouattour M; Paradis V
    Eur J Gastroenterol Hepatol; 2020 Oct; 32(10):1364-1372. PubMed ID: 31895908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.
    Degasperi E; Perbellini R; D'Ambrosio R; Uceda Renteria SC; Ceriotti F; Perego A; Orsini C; Borghi M; Iavarone M; Bruccoleri M; Rimondi A; De Silvestri A; Sangiovanni A; Lampertico P
    Aliment Pharmacol Ther; 2022 Feb; 55(3):350-359. PubMed ID: 34738664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.
    Jitpraphawan O; Ruamtawee W; Treewatchareekorn M; Sethasine S
    World J Gastroenterol; 2024 May; 30(17):2343-2353. PubMed ID: 38813057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
    Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
    J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of serum protein induced by vitamin K absence (PIVKA-II), serum a-fetoprotein and their combination for hepatocellular carcinoma among Caucasian cirrhotic patients with diagnostic or non-diagnostic serum a-fetoprotein levels.
    Syriha A; Pantzios S; Mandilara D; Galanis P; Stathopoulou I; Barla G; Elefsiniotis I
    Cancer Med; 2024 Feb; 13(3):e6825. PubMed ID: 38361401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
    Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
    Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of serum alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels in patients with hepatocellular carcinoma following interventional radiology.
    Minakuchi K; Murata K; Kaminoh T; Takada K; Takashima S; Nakamura K; Onoyama Y
    Radiat Med; 1993; 11(6):231-6. PubMed ID: 7512271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma.
    Wang G; Lu X; Du Q; Zhang G; Wang D; Wang Q; Guo X
    Sci Rep; 2020 Aug; 10(1):13519. PubMed ID: 32782270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
    BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.